AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177–191 of human growth hormone, modified with a tyrosine residue. Developed by Metabolic Pharmaceuticals, it was designed to retain the fat-metabolizing properties of growth hormone without its growth-promoting and insulin-desensitizing effects.
Mechanism and Rationale
Full-length growth hormone has multiple biological effects, including fat metabolism (lipolysis), growth promotion, and insulin resistance. The C-terminal fragment AOD-9604 was identified as potentially responsible for hGH's lipolytic properties. By isolating and synthesizing this fragment, researchers aimed to capture metabolic benefits while avoiding the undesirable effects of exogenous GH administration.
Lipolysis Research
Animal studies demonstrated that AOD-9604 stimulates lipolysis (breakdown of stored fat) and inhibits lipogenesis (new fat formation) through mechanisms that appear to involve beta-3 adrenergic receptor signaling rather than the growth hormone receptor pathway, potentially explaining its selectivity for fat metabolism over growth promotion.
Clinical Trial History
AOD-9604 progressed through Phase 1, 2, and early Phase 3 clinical trials for obesity treatment, making it one of the few peptide weight loss compounds with substantial human safety data. Phase 2 results showed modest weight loss benefits, though Phase 3 results were insufficient to support regulatory approval for obesity indications.
Cartilage Repair Research
Following the obesity program, research interest shifted toward AOD-9604's potential applications in osteoarthritis and cartilage repair. Preclinical studies suggested potential chondroprotective effects, and the compound received GRAS (Generally Recognized as Safe) status from the FDA based on its clinical trial safety profile.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.